Recently conducted research has investigated the EPH/ephrin pathway for the design of molecularly targeted therapies and novel chemotherapeutic agents to control local tumors and prevent metastatic disease in rhabdomyosarcoma. This evidence concerns the gene EPHA1 and rhabdomyosarcoma.